LAMC2 (Laminin subunit gamma 2)

In this study, we identify the tumor invasive margin as a critical determinant of immunotherapy resistance in ESCC. By defining the specific spatial markers and molecular architecture of an immune-privileged niche associated with the immune-exclusion barrier, our findings demonstrate the value of spatially resolved microenvironmental analysis. Moreover, we propose that therapeutic targeting of this boundary niche represents a promising strategy to overcome resistance in ESCC.

This study establishes S-nitrosylation as a crucial PTM in pancreatic cancer and introduces a robust machine-learning-based prognostic model. LAMC2 is identified as a key oncogenic effector connecting S-nitrosylation dysregulation to tumor aggressiveness, providing novel prognostic and therapeutic insights for pancreatic cancer management.

Our findings suggest that LAMC2 promotes GBC progression and metastasis, potentially by regulating the TGF-β signaling pathway. Therefore, LAMC2 could serve as a potential prognostic biomarker and therapeutic target for GBC.

Moreover, a Cox regression-based prognostic model constructed using LAMC2-associated genes exhibited robust predictive performance across multiple independent cohorts. Our findings identify LAMC2 as a key mediator of F. nucleatum-induced CRC metastasis and highlight it as both a prognostic biomarker and a potential therapeutic target.

zDHHCs-mediated palmitoylation and its regulatory gene network critically shape pancreatic cancer heterogeneity, immune microenvironment, and prognosis. The PRGS model provides a novel molecular tool for patient stratification and may inform the development of precision therapies targeting palmitoylation-driven pathways in PC.

Six potential therapeutic agents targeting ITGA2, LAMB3, and FN1 were identified. Three genes and associated known drugs identified in this study may serve as potential targets for treating the coexistence of the two diseases.

An 18-protein (PURB, SDCBP2, CD2BP2, GALM, SERPINA3, OAS3, FAN1, ZPR1, KRT2, NUDT2, SMNDC1, SERPINA4, CUTA, WDR36, POSTN, CLEC11A, PEX14, and PI4KA) risk score demonstrated independent prognostic significance for overall survival, and recurrence, and was validated in an independent proteomic dataset generated using a different proteomic technology. This study introduces four novel prognostic PDA subtypes and an 18-protein risk score, validated in an independent dataset, which show promise for improving survival prediction and could serve as a valuable tool for personalized treatment guidance.

Furthermore, the increasing importance of LAMC2 as a viable target for cancer therapy is explored. This review aims to provide a thorough overview of LAMC2's involvement in cancer progression, prognostic implications, potential therapeutic target, and involved signaling pathway, and to outline future research directions in this promising field.

We successfully established a murine cell line LLC-PLM that can serve as a valuable tool for studying pleural metastasis and MPE.

These hits exhibited lower free energies (ΔG) as compared to the benchmark inhibitors, Galunisertib and Vactosertib. The results offer valuable insights into the binding mechanism of protein TGFßR1 and its role in the disease, suggesting that targeting the TGF-ß signaling pathway may represent a promising therapeutic strategy.

FOXE1 promotes lung cancer progression and BM by upregulating LAMC2. Targeting the FOXE1-LAMC2 pathway may improve the efficacy of preoperative CRT and offers a promising strategy for therapeutic intervention in lung cancer patients at high risk of BM.

The key genes are mainly concentrated within signaling pathways such as metabolic pathways, fatty acid metabolism, and cancer pathways. Twelve differentially expressed mRNAs in the co-expression network can be used as biomarkers and intervention targets for the diagnosis and treatment of alcoholic hepatitis.